Drug firm Lupin today said it has been granted final approval by the United states Food and Drug Administration (USFDA) for antihistamine Desloratadine tablets, used for treating allergies.
The approval has been given to Lupin Pharmaceuticals, Lupin's wholly owned US subsidiary for Desloratadine tablets in the strength of 5 mg, the company said in a filing to the Bombay Stock Exchange (BSE).
Desloratadine tablets 5 mg are generic version of Clarinex tablets 5 mg of US-based drug major Schering-Plough.
According to IMS Health, clarinex tablets have recorded sales of $229 million for this year, the company added.
The company has filed 132 abbreviated new drug applications for this financial year, of which 45 have been approved by the USFDA.
Shares of Lupin were trading today at Rs 446.15 on the BSE in the afternoon trade, up 0.30 per cent from its previous close.
